Medical Oncology Thesis Topics

Ø  An extensive collection of over 100,000 thesis topics is offered on the website, with approximately 10,000 topics per specialty, including a dedicated section for Medical Oncology thesis topics.

Ø  Numerous medical journals have been meticulously reviewed to compile a list of recent Medical Oncology thesis topics, ensuring resident doctors have access to the latest trends and developments within the field.

Ø  Through personalized WhatsApp guidance, support is provided to resident doctors throughout the thesis process across all broad specialties and super-specialties, including Medical Oncology.

Ø  Thesis Protocol and Synopsis: Assistance is given in developing a well-structured protocol and synopsis specifically tailored for Medical Oncology thesis topics.

Ø  Sample Size Determination: For studies on Medical Oncology thesis topics, guidance is offered to determine the correct sample size using complex formulas and pilot studies, ensuring methodological precision.

Ø  Review of Literature: Comprehensive support is available for conducting a thorough literature review, establishing a strong foundation for Medical Oncology thesis topics.

Ø  Statistical Methods: Advice is provided on selecting and applying the most appropriate statistical methods to meet the objectives of Medical Oncology thesis topics.

 

Ø  This platform consolidates both conventional and new Medical Oncology thesis topics, saving residents time and offering a streamlined research process.

Medical Oncology Thesis Topics

  1. Efficacy of immune checkpoint inhibitors in metastatic melanoma: A multicenter cohort study analyzing survival outcomes.
  2. Role of liquid biopsy in monitoring treatment response and detecting resistance mutations in non-small cell lung cancer.
  3. Impact of adjuvant chemotherapy on overall survival in patients with early-stage triple-negative breast cancer: A systematic review and meta-analysis.
  4. Outcomes of targeted therapy with PARP inhibitors in BRCA-mutated ovarian cancer: A multicenter retrospective analysis.
  5. Comparative effectiveness of neoadjuvant chemotherapy versus chemoradiation in locally advanced rectal cancer: A prospective cohort study.
  6. Analysis of the prognostic significance of circulating tumor DNA in patients with advanced colorectal cancer undergoing chemotherapy.
  7. Long-term outcomes of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: A multicenter retrospective study.
  8. Evaluation of the efficacy and safety of CAR-T cell therapy in relapsed or refractory diffuse large B-cell lymphoma.
  9. Role of next-generation sequencing in identifying actionable mutations in patients with advanced solid tumors: A prospective observational study.
  10. Impact of maintenance therapy with PARP inhibitors on progression-free survival in patients with recurrent platinum-sensitive ovarian cancer.
  11. Comparative effectiveness of single-agent versus combination immunotherapy in metastatic renal cell carcinoma: A multicenter cohort study.
  12. Role of PD-L1 expression as a predictive biomarker for response to immune checkpoint inhibitors in advanced non-small cell lung cancer.
  13. Outcomes of high-dose chemotherapy with autologous stem cell rescue in pediatric patients with high-risk neuroblastoma: A retrospective cohort study.
  14. The association between tumor mutational burden and response to immune checkpoint blockade in solid tumors: A systematic review and meta-analysis.
  15. Efficacy of combined BRAF and MEK inhibition in patients with BRAF V600-mutant metastatic melanoma: A real-world evidence study.
  16. Outcomes of trastuzumab deruxtecan in HER2-positive metastatic breast cancer after progression on multiple lines of therapy: A multicenter study.
  17. Role of genetic profiling in guiding targeted therapy for patients with advanced gastrointestinal stromal tumors: A prospective cohort study.
  18. Analysis of the efficacy of pembrolizumab in mismatch repair-deficient colorectal cancer: A multicenter retrospective analysis.
  19. Comparative effectiveness of aromatase inhibitors versus tamoxifen in postmenopausal women with hormone receptor-positive breast cancer.
  20. The impact of chemotherapy-induced peripheral neuropathy on quality of life in cancer patients: A prospective observational study.
  21. Cross-sectional study on the prevalence of anemia in patients undergoing chemotherapy for solid tumors and its impact on treatment outcomes.
  22. Cross-sectional analysis of the incidence and risk factors of venous thromboembolism in patients with advanced cancer receiving immunotherapy.
  23. Prevalence of cognitive impairment in cancer survivors post-chemotherapy: A cross-sectional study using neuropsychological testing.
  24. Cross-sectional study on the use of complementary and alternative medicine among patients with advanced cancer: A survey-based analysis.
  25. Prevalence and impact of cancer cachexia on treatment outcomes in patients with gastrointestinal malignancies: A cross-sectional study.
  26. Cross-sectional analysis of the relationship between sarcopenia and outcomes in elderly cancer patients undergoing chemotherapy.
  27. Prevalence of distress and its correlates in patients with advanced cancer: A cross-sectional study using validated assessment tools.
  28. Cross-sectional study on the impact of socioeconomic factors on access to cancer care and treatment outcomes in a diverse patient population.
  29. Prevalence and predictors of opioid use disorder in patients with cancer-related pain: A cross-sectional study.
  30. Cross-sectional analysis of immune-related adverse events in patients receiving checkpoint inhibitors for metastatic melanoma.
  31. Prevalence of cardiovascular toxicities in breast cancer survivors treated with anthracyclines: A cross-sectional study.
  32. Cross-sectional study on the prevalence and risk factors of chemotherapy-induced febrile neutropenia in pediatric oncology patients.
  33. Prevalence of fatigue and its association with clinical outcomes in patients with metastatic cancer: A cross-sectional study.
  34. Cross-sectional study on the impact of smoking status on treatment response and outcomes in lung cancer patients receiving immunotherapy.
  35. Prevalence of renal impairment in multiple myeloma patients undergoing chemotherapy: A cross-sectional study.
  36. Cross-sectional analysis of the impact of comorbidities on survival outcomes in elderly patients with hematologic malignancies.
  37. Prevalence of anxiety and depression in caregivers of cancer patients: A cross-sectional study in a tertiary care setting.
  38. Cross-sectional study on the incidence of radiotherapy-induced skin toxicity in breast cancer patients: A survey-based analysis.
  39. Prevalence of liver toxicity in patients with colorectal cancer treated with irinotecan-based chemotherapy: A cross-sectional study.
  40. Cross-sectional study on the impact of diet and nutrition on treatment outcomes in cancer patients receiving chemotherapy.
  41. Comparative study on the efficacy and safety of PD-1 inhibitors versus PD-L1 inhibitors in patients with advanced melanoma.
  42. Comparative outcomes of stereotactic body radiotherapy versus conventional radiotherapy in patients with oligometastatic non-small cell lung cancer.
  43. Comparative study of the impact of early versus late palliative care consultation on quality of life in advanced cancer patients.
  44. Comparative effectiveness of different chemotherapy regimens in the first-line treatment of advanced gastric cancer: A multicenter cohort study.
  45. Comparative outcomes of proton therapy versus photon therapy in pediatric patients with medulloblastoma: A retrospective cohort study.
  46. Comparative study on the efficacy of different tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma.
  47. Comparative analysis of the survival outcomes of patients with HER2-positive breast cancer treated with trastuzumab versus trastuzumab emtansine.
  48. Comparative effectiveness of different maintenance strategies after first-line chemotherapy in advanced epithelial ovarian cancer.
  49. Comparative study of the impact of continuous versus intermittent dosing of tyrosine kinase inhibitors in chronic myeloid leukemia.
  50. Comparative analysis of the outcomes of hypofractionated versus conventional fractionated radiotherapy in prostate cancer.
  51. Comparative study on the effectiveness of combination versus sequential therapy with immune checkpoint inhibitors in metastatic melanoma.
  52. Comparative outcomes of neoadjuvant chemotherapy versus chemoradiation in patients with locally advanced esophageal cancer.
  53. Comparative study of the impact of targeted therapy versus chemotherapy on quality of life in patients with metastatic colorectal cancer.
  54. Comparative effectiveness of laparoscopic versus open surgery in the management of early-stage colon cancer: A multicenter cohort study.
  55. Comparative analysis of the outcomes of autologous versus allogeneic stem cell transplantation in multiple myeloma patients.
  56. Comparative study on the efficacy of different immune checkpoint inhibitors in the treatment of advanced head and neck cancers.
  57. Comparative outcomes of adjuvant chemotherapy versus no adjuvant therapy in patients with stage I testicular cancer.
  58. Comparative study on the impact of dose-dense versus standard chemotherapy regimens in the treatment of high-risk breast cancer.
  59. Comparative analysis of the safety and efficacy of different bisphosphonates in the management of bone metastases in cancer patients.
  60. Comparative study on the role of genetic testing in guiding targeted therapy versus standard care in advanced cancer patients.
  61. Recent advances in the use of chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies: A review of clinical trials.
  62. Advances in understanding the mechanisms of resistance to immune checkpoint inhibitors in melanoma: Implications for future therapies.
  63. Recent developments in the role of tumor microenvironment in cancer progression and treatment resistance: A review.
  64. Advances in the management of chemotherapy-induced peripheral neuropathy: From pharmacologic to non-pharmacologic strategies.
  65. Recent advancements in the use of liquid biopsy for early detection and monitoring of minimal residual disease in solid tumors.
  66. Advances in the use of artificial intelligence and machine learning in cancer diagnosis and treatment planning: Current applications and future directions.
  67. Recent developments in the understanding of the molecular biology of triple-negative breast cancer: Implications for targeted therapy.
  68. Advances in the use of poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of advanced prostate cancer: A review of recent evidence.
  69. Recent advances in the role of microbiome in cancer immunotherapy: From bench to bedside.
  70. Advances in the management of hepatocellular carcinoma: From local therapies to systemic treatments.
  71. Recent developments in the understanding and management of brain metastases: From targeted therapies to immunotherapy.
  72. Advances in the use of biomarker-driven therapies in the management of lung cancer: Current status and future prospects.
  73. Recent advancements in the role of epigenetic therapies in hematologic malignancies: A focus on clinical outcomes.
  74. Advances in the management of cancer-associated thrombosis: From anticoagulation to targeted therapies.
  75. Recent developments in the understanding of cancer metabolism and its implications for new therapeutic strategies.
  76. Advances in the role of combination therapy in the management of advanced renal cell carcinoma: A review of recent clinical trials.
  77. Recent advances in the treatment of HER2-positive breast cancer: From chemotherapy to targeted therapies.
  78. Advances in the use of checkpoint inhibitors in the management of advanced gastrointestinal malignancies: A review.
  79. Recent developments in the understanding of immune evasion mechanisms in cancer: Implications for new therapeutic strategies.
  80. Advances in the management of chronic lymphocytic leukemia: From chemoimmunotherapy to targeted agents.
  81. Analysis of recent studies on the efficacy of bispecific antibodies in the treatment of multiple myeloma.
  82. A review of recent research on the role of CDK4/6 inhibitors in the management of hormone receptor-positive breast cancer.
  83. Recent studies on the role of radiomics and genomics in predicting treatment response in non-small cell lung cancer.
  84. Review of recent literature on the use of oncolytic viruses in the treatment of advanced solid tumors.
  85. Recent advancements in the management of soft tissue sarcomas: From surgery to novel systemic therapies.
  86. Analysis of recent research on the outcomes of neoadjuvant immunotherapy in patients with resectable melanoma.
  87. Recent studies on the role of targeted therapy in the management of metastatic uveal melanoma: Current perspectives.
  88. Review of recent advancements in the management of early-stage triple-negative breast cancer: From surgery to systemic therapies.
  89. Recent studies on the impact of stereotactic radiosurgery in the management of brain metastases from breast cancer.
  90. Analysis of recent research on the use of pembrolizumab in the treatment of advanced squamous cell carcinoma of the head and neck.
  91. Review of recent literature on the use of peptide receptor radionuclide therapy in neuroendocrine tumors.
  92. Recent advancements in the understanding of the role of tumor mutational burden in predicting response to immunotherapy.
  93. Analysis of recent studies on the outcomes of combination therapy with immunotherapy and chemotherapy in metastatic gastric cancer.
  94. Review of recent advancements in the management of metastatic castration-resistant prostate cancer: From AR inhibitors to PARP inhibitors.
  95. Recent studies on the use of selective estrogen receptor degraders in the management of advanced breast cancer.
  96. Analysis of recent research on the impact of dose-escalation strategies in radiotherapy for locally advanced pancreatic cancer.
  97. Review of recent advancements in the use of immune checkpoint inhibitors in the treatment of Hodgkin lymphoma.
  98. Recent studies on the role of targeted therapy in the management of advanced basal cell carcinoma.
  99. Analysis of recent research on the use of hypofractionated radiotherapy in the treatment of localized prostate cancer.
  100. Review of recent advancements in the management of gastrointestinal stromal tumors: From surgery to targeted therapies.
Premium Medical Oncology Thesis Topics
international journal of medical case reports
medical publications
dental thesis topics

© 2024 SS Topics

© 2024 SS Topics

Don`t copy text!
×